Miravo Healthcare™ Announces 2021 and Fourth Quarter Results

Blexten Canadian Prescriptions Increased 21% Year-Over-Year –
Cambia Canadian Prescriptions Increased 8% Year-Over-Year –

 

Miravo to Host Conference Call/Audio Webcast March 28th at 11:00 a.m. ET

Mississauga, Ontario, Canada – March 28, 2022 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months and year ended December 31, 2021.  For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Consolidated Financial Statements for the three months and year ended December 31, 2021 which are available on the Company’s website (www.miravohealthcare.com).  All figures are in Canadian dollars, unless otherwise noted.

Read full release here.